How Early Clinical Development in Australia can Enable U.S. Biotech’s Maintain Pace with China
In the race to clinical milestones, every single day counts. We recently hosted a webinar exploring how early clinical development in Australia can enable U.S. biotechs to maintain pace with China. With delays costing sponsors up to $500,000 per day, moving efficiently from discovery to the clinical stage is a critical priority.During the session hosted by our CEO, Greg Plunkett, we highlighted how Australia offers a strategic advantage. By leveraging rapid trial execution and generating globally accepted data, U.S. sponsors can secure predictable progress and accelerate their path to market. Watch the full webinar to dig a little deeper and learn how to build momentum for your clinical programme
